Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term inhaled mannitol in cystic fibrosis
NL-OMON32987Phase 3Active, not recruiting
- Sponsor
- Pharmaxis
- Start
- Sep 2009
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bronchitol in cystic fibrosis (CF) (3 arms), sponsored by Pharmaxis. Primary endpoint: Change in absolute FEV1. Started Sep 2009; status: active, not recruiting.
02
Drugs
Bronchitol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON32987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32987.